This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
11/4/2026
Ladies and gentlemen, thank you for standing by. Welcome to our QDIS Biotherapeutics third quarter 2026 earnings conference call. At this time, all participants are in the listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you would need to press star 1-1 on your telephone. You would then hear an automated message advising your hand is raised. And to withdraw your question, please press star 1-1 again. Please be advised that today's conference is being recorded. I would like now to turn the conference over to Brian Schoelkopf, Head of Investor Relations. Please go ahead.
Thank you, Michelle. Good afternoon, everyone, and thank you for joining us today to review our third quarter 2026 financial results and business update. Slides for today's call are available on the Investor section of the RQDIS website. Joining me on the call today are Frank Watanabe, President and CEO of Arcudis, Rob Lefricke, Chief Commercial Officer, Patrick Burnett, Chief Medical Officer, and Latha Vairavan, Chief Financial Officer. I would like to remind everyone that we will be making forward-looking statements during this call. These statements are subject to certain risks and uncertainties, and our actual results may differ. We encourage you to review all of the company's filings with the Securities and Exchange Commission, including descriptions of our business and risk factors. With that, I'll now turn the call over to Frank to begin today's call.
Thanks, Brian, and good afternoon, everybody. As always, we appreciate you joining us for our quarterly update call. It's hard to believe that we're now in the fourth and final quarter of 2026. As I start this afternoon, I'm going to start with a review of the business and our progress. that we've made in our third quarter as we continue to execute against our grow, expand, and build corporate strategy and to deliver on our mission to bring meaningful innovation to individuals living with chronic inflammatory skin diseases. I'll then take a couple of minutes to address a question that we've been getting a lot recently, namely our approach to the application of artificial intelligence at Arcutis. I'll then turn it over to Rob for a commercial update, then Patrick will provide an update on our R&D programs and initiatives, and we'll finish with a review of the quarter's financial results from Latha before we open it up to your questions. Okay, I'm on slide five. It has been a year since we unveiled our three-pillar grow, expand and build strategy to sustain near and long-term corporate growth. And in the third quarter, once again, we made notable progress across all three pillars. I'll start with the grow pillar, comprising activities that are designed to strengthen our core Zareeb business across our three current indications Plasteriasis, Atopic Dermatitis, and Seborrheic Dermatitis. In late September, we announced an incredibly exciting new partnership with world champion gymnast Simone Biles to launch our Skin to Believe In awareness campaign. The goal of this ambitious multi-channel campaign is to encourage nearly 36 million Americans living with either eczema or seborrheic dermatitis to talk to their doctor about long-term steroid-free topical treatment options for their chronic skin diseases. Through the campaign, Simone will share her own experience of living with and managing her seborrheic dermatitis and eczema, including her strategies in grease, foam, and cream. It's truly an honor for her to be partnering with Simone, one of the most recognized and well-respected athletes in the world. Simone has been an authentic and trusted advocate of health for hormonal issues, making her an extraordinarily powerful brain ambassador. By sharing her story about her challenges of living with her skin condition, Some who are not only helping out others, but taking control of their health by speaking with their health care provider about advanced care. This awareness campaign is meaningful in its own right and is also synergistic with our other commercial initiatives, such as virtual health and our primary care and pediatric sales force that we've been rolling out throughout the year. Collectively, these initiatives are designed to generate awareness of the differentiated therapeutic profile Thank you for joining us today. that will evaluate Xareve Cream 0.3% for the treatment of moderate to severe atopic dermatitis. Xareve Cream 0.15% is already embedded as an important treatment option for clinicians for the treatment of mild to moderate atopic dermatitis. And the intent of this trial, as Patrick will detail shortly, is to evaluate Xareve in these more severe patients who need similarly effective and well-tolerated treatment options for the management of their chronic inflammatory skin disease as a list of your patients. We're also eagerly awaiting the February 2027 PDUCA date for Dereave Cream 0.05% as a treatment for mild to moderate atopic dermatitis in infants aged 3 to 24 months, with launch preparations already underway. This expanded indication will be based on the strength of the data from our Phase II Integument Infant Trial. We're excited by the potential to bring an effective non-cerebrotopical treatment Thank you. Thank you. Thank you. So now turning to the expand pillar and our ongoing efforts to potentially broaden the application of Xareeb to individuals with unmet needs across a range of additional inflammatory skin conditions as guided by the expansive body of compelling case reports with Xareeb. As we've announced previously, we've now completed enrollment in our phase two proof of concept trial of Vitiligo. We remain on track to provide a readout from the Vitiligo trial in the fourth quarter of this year, as well as the decision on whether we will advance the program based on those data. And we continue to enroll the Hydretinitis Supertiva or HS Phase II proof-of-concept trials, and we anticipate a similar readout for the HS program late in the first quarter of 2027. We're also very excited about a new trial that we're just beginning that will evaluate the use of Zareve to treat the debilitating skin rashes that affect up to half of all patients treated with life-saving checkpoint inhibitor therapies like Keytruda and Updivo. Ironically, these skin rashes are an indication of treatment effect, but they also frequently lead patients to reduce or even discontinue their treatment. So a treatment option with a favorable safety and efficacy profile for these common side effects would be very well received. And we continue to evaluate other potential indications and expect to announce additional Phase II POC studies in the coming quarters. The breadth and ambition of our clinical pursuits with Zareeb continue to be unrivaled in the branded non-steroidal topical segments. They are enabled by Xerox's differentiated therapeutic profile and the distinct and pleiotropic mechanism of action. And while we're advancing them against the backdrop of increasing awareness of the harmful side effects of extended or inappropriate use of corticosteroids and a growing movement to shift the standard of care to advance non-steroidal topical treatments. Put simply, we believe we are at the right time, in the right place, with the right drug. And finally, turning to the build pillar and our efforts to deepen our innovative pipeline beyond Zariv, where we continue to make progress on the Phase 1A1B trial of ARQ234, our novel biologic targeting CD200R as a potential treatment for moderate to severe atopic dermatitis. Additionally, as we've highlighted in previous calls, we anticipate that external innovation will play a key role in our pipeline expansion efforts. And to that end, we continue to actively evaluate a range of external assets. There's a great deal of emerging scientific and therapeutic innovation across the dermatology and adjacent INI landscape. Potential opportunities for impact are far-reaching and very exciting. Finally, as Latha will describe, we had another strong quarter financially. The sustained level of performance across our core Zareve business and the cash flow it is generating is enabling us to continue to invest in innovation, securing the foundation for the long-term success of our QDIS. On our Q2 call, you'll recall that we increased our full year 2026 net revenue guidance by $45 million at the midpoint to between $525 and $540 million, taking into consideration our strategic portfolio of investments and the continued strength of our core business. With visibility into the remainder of the year and the strength of our Q3 results, today we are further increasing that guidance range to between $535 and $545 million. Before detailing our results for the quarter, I'd like to spend a moment answering a question that we've been increasingly receiving, and I'm on slide six now, namely our approach to adopting AI at Arcutis. And it's clear to everyone that artificial intelligence is having and will continue to have a meaningful impact on biotech and nearly every other sector of business. But as I've remarked previously, when all you have is a hammer, everything looks like a nail. And we believe there's a risk that many companies will overinvest in AI programs that yield little or no tangible benefit to their customers and shareholders. At Arcutis, we are taking a measured and intentional approach to leveraging the power of AI in our business. We see the potential, but remain very thoughtful about when we use it and also how we protect our data, an essential issue in a knowledge-intensive business like biotech. Our disciplined approach begins by evaluating when and where AI can be an accelerator to our business. One key question has to be whether AI offers distinct advantages over other traditional approaches. And where AI makes sense, we look to pursue those projects with the greatest impact on our highest priority business objectives. And every AI project needs to have measurable value with the potential for a high return on investment. Lastly and critically, we scrutinize every potential AI project to ensure we can protect our proprietary data and information. Using this disciplined approach, we have already identified more than 30 discrete use cases for AI across our business, some of which have already been deployed and many more that are in the production phase. For example, we've recently equipped our field sales team with an industry-leading AI-enabled set of tools that help them harness all of the information at our disposal to better analyze their business, prioritize which clinicians to call on, what clinical data might be most relevant for the clinicians they interact with, and how best to present derived materials. These efforts are already having a positive impact and becoming an important component of our reps toolkit. Rob and Patrick and I were out in the field last week with our team and we were impressed at how our team is rapidly leveraging these new tools to enhance their effectiveness. We're also partnering with companies deploying AI-enabled prescription workflow platform to streamline the post-prescription process for medical offices and that facilitates a more seamless and efficient process for patients to receive those re-prescriptions once written. Recently, our medical affairs team and our IT group partnered to utilize AI to analyze more than 30 million FDA safety reports and over 1,000 FDA product labels to better highlight the need for a revision of topical steroid labeling. This research led to an important publication in a peer-reviewed journal, which is helping to lay the foundation for regulatory action on topical steroids. and a final example is our finance team's use of multiple AI-enabled tools to improve efficiency and accuracy of critical business processes such as accounts receivable. Having seen early success with such thoughtful implementations of AI to our business, we will continue to pursue measured and intentional deployments of AI. It's just the latest example of meaningful innovation at the forefront of what we do here at Arcutis. Now, before we proceed any further, I'm going to share what is, for me, very exciting news personally and for the Arcutus team. That is, today, I'm pleased to announce that Rob Lepicki has agreed to stay on permanently as our Chief Commercial Officer. As I mentioned to you on our Q2 call, Rob brings a wealth of experience leading best-in-class commercial teams in the information and immunology space and in driving rapid sales expansion to build blockbuster franchises. Rob and I have known each other for More than two decades since our time working together on Enroll, and I can say without reservation, he is one of the finest commercial leaders I have ever had the privilege of working with in my years in industry. Unsurprisingly, Rob has effortlessly stepped in the CCO role and has already gained a firm handle on our strategic vision and the near and long-term plans for Zuri. He is making a significant impact as we continue to execute in 2026 and prepare for a very busy 2027. The leadership, commercial mouse, and drive that Rob brings to bear are ideally matched to the moment that we are at with Zarif, and I can think of no better individual to drive Zarif to its full blockbuster potential. And with that, I'll now hand it over to Rob for his initial commentary on the business and third quarter commercial results.
You're reading a preview of the ARQT Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing